International Journal of Radiation Oncology*Biology*Physics
Clinical investigationLiverTargeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: Clinical Phase I/II trials
Introduction
Primary liver cancer ranks second among cancers as a cause of death, owing to its high incidence rate, rapid progression, poor prognosis, and tumor recurrence (1). The mean natural survival time of patients with hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is only 3.2 months, and the 5-year survival rate is 5% (1). Less than 20% of HCC patients are fit for traditional therapies, such as surgery or chemotherapy (1, 2). In addition, at least 85% of HCC patients in China also have liver cirrhosis, which makes therapy more difficult (1). Since the 1980s, radioimmunotherapy (RIT) has become a promising therapy for tumors, because the specificity of the antibodies and the killing power of the radionuclides tend to bring about better clinical efficacy with fewer side effects.
Iodine (131I) metuximab injection (brand name, Licartin; Chengdu Hoist Hitech Co., Ltd., Chengdu, China) is an iodine 131I-labeled murine monoclonal antibody (mAb) HAb18 F(ab’)2 fragment against the HCC-associated antigen HAb18G/CD147. The mAb HAb18 (immunoglobulin G1) was obtained by using a cell suspension extracted from fresh human HCC tissues to immunize BALB/c mice and to prepare hybridoma (3, 4, 5). Its antigen, HAb18G/CD147, a member of the CD147 family, was highly expressed on HCC cells (6, 7). The binding rate of HAb18 to human 7721 hepatoma cells, determined by flow cytometry, was 99.55%, and the mean fluorescent intensity was 171.31. Immunohistochemistry performed with HAb18 showed that the positive rate of HCC staining was 75% (39 of 52) without cross-reaction to normal tissues (5). Metuximab was prepared by pepsin digestion of HAb18 to remove the Fc fragment. Its molecular weight ranged from 94 kd to 98 kd by analysis of nonreductive sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and the molecular weight of the heavy chain and light chain ranged 26–28 kd and 21–23 kd, respectively, by reductive SDS-PAGE analysis. Its titer was >1:8000 by immunofluorescence staining analysis on HCC cells, and its affinity constant to the recombined HAb18G/CD147 molecule was determined to be 6.32 × 10−10 mol/L by surface plasmon resonance analysis. A pharmacokinetics study conducted in BALB/c mice showed that the blood clearance of the iodine (131I) metuximab injection fitted a biphasic model, and the half life (t1/2) in blood was 34.61 h (8). Biologic distribution analysis of metuximab in a human HCC xenografts model in BALB/c nude mice showed that the tumor/nontumor radiation absorbed dose ratio ranged from 2.51 ± 0.69 to 18.60 ± 2.05 (4, 9). The 30% and 50% effective doses of the iodine (131I) metuximab injection were, respectively, 133.2 and 370 MBq/kg for mice, equal to 15.54 and 43.29 MBq/kg for humans. The nontoxic dose in the long-term toxicity test was 277.5 MBq/kg for rats, equal to 45.88 MBq/kg for humans. The results of safety pharmacology studies showed that iodine (131I) metuximab injection caused no impairment to cardiovascular, respiratory, or nervous systems. The above results have all been sanctioned by the China State Food and Drug Administration (SFDA).
In the preliminary clinical study (approved by the Health Bureau of Shaanxi Province, China, 1999), the evidence of anti-HCC effects in 7 of 9 assessable HCC patients (77.78%) was observed, of whom 1 had complete response (CR), 1 partial response (PR), 1 minor response (MR), and 4 stable disease (SD). After the preliminary clinical study, we conducted Phase I and Phase II clinical trials to assess the safety, pharmacokinetics, and efficacy of iodine (131I) metuximab injection in HCC patients.
Section snippets
Patient selection
Eligible subjects for this study were patients aged 18–75 years, who had been clinically definitely diagnosed with HCC but who had no indication for surgical treatment, who had an anticipated survival time of >3 months, and whose Karnofsky Performance Score (KPS) was >60. The diagnoses were made mainly by computed tomography (CT) scans, alpha fetoprotein level detection, and analysis of clinical history and symptoms. The possible candidates who were excluded from our study were patients who had
Patients characteristics
At the four centers mentioned above, 134 eligible patients were randomly enrolled. In the Phase I study, 22 men and 6 women, aged 24–75 years (mean ± standard deviation: 53 ± 10 years), were enrolled between February and June 2001. In Phase II, 97 men and 9 women, aged 27–75 years (51 ± 12 years), were enrolled between March 2002 and August 2003. The median follow-up was 15 months (range, 2–33 months). The majority of the patients enrolled in the present study were male; men are more
Discussion
Radionuclide in radiolabeled-antibody, using antibody as the carrier, can be targeted to and concentrated in tumor tissues to kill more tumor cells while causing as little injury as possible to normal tissues. Thus, compared with chemotherapy or radiotherapy, RIT has few toxic effects. The effective killing range of radionuclide can reach the path length of 830 μm, which amounts to more than 50 tumor cells, and the surrounding tumor cells, which are not bound with antibody, can also be killed.
Acknowledgments
The authors thank Y. F. Liu, Y. F. Sui, J. L. Deng, X. Y. Yao, H. Tang, L. Xie, Y. Zhang, M. Zhang, C. M. Fan, Y. M. Zhang, M. D. Jiang, B. X. Su, M. F. Ren, R. Li, D. L. Luo, G. C. Ge, and F. Peng for their contributions to this study.
References (35)
Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function
Curr Top Dev Biol
(2003)- et al.
Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma
Crit Rev Oncol Hematol
(2001) - et al.
The involvement of HAb18G/CD147 in regulation of store-operated calcium entry and metastasis of human hepatoma cells
J Biol Chem
(2001) - et al.
cGMP-regulated store-operated calcium entry in human hepatoma cells
Cell Biol Int
(2001) - et al.
Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma
Int J Radiat Oncol Biol Phys
(2003) - et al.
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
Hepatology
(2002) - et al.
Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma
Hepatology
(1997) Review
Review on treatment of primary liver cancer
- et al.
Monoclonal antibody HAb18 to human hepatoma
Monoclonal Antibodies
(1990)
Localization of hepatocellular carcinoma with monoclonal antibodies
Zhonghua Yi Xue Za Zhi
Pharmacokinetics of monoclonal antibody HAb18 and its F(ab’)2 and Fab fragments in mice
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
Radiolocalization of human hepatoma with anti-human hepatoma monoclonal antibodies and its F(ab’)2 in tumor-bearing nude mice
Zhonghua Yi Xue Za Zhi
Toxicity test
Cited by (148)
CD147 and MMPs as key factors in physiological and pathological processes
2023, Biomedicine and PharmacotherapyAdvanced radionuclides in diagnosis and therapy for hepatocellular carcinoma
2022, Chinese Chemical LettersScreening for a <sup>177</sup>Lu-labeled CA19–9 monoclonal antibody via PET imaging for colorectal cancer therapy
2022, Chinese Chemical LettersChimeric antigen receptor T cells targeting CD147 for non-small cell lung cancer therapy
2022, Translational OncologyModified Therapeutic Antibodies: Improving Efficacy
2021, Engineering
Supported by Key Technologies R&D Program of China 2002AA2Z3441 (H.J.B.); Hi-tech Research and Development Program of China 2001AA215061 (P.Z.) and 2002AA217011 (L.M.); and National Natural Science Foundation of China 39989002 and 30070842 (Z.N.C.).
- 1
Z.-N.C., L.M., J.X., F.S., and Q.Z. contributed equally to this work.